ArticleCell communication and signaling : CCS2022

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.

Ian A MacNeil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.